Trial
NCT01253668
Brivanib Metastatic Renal Cell Carcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
—
Condition
Renal Cell Carcinoma
Intervention
Brivanib alaninate
Why stopped
In November 2012, this study was permanently closed to new accrual at the request of the drug manufacturer (BMS), who decided not to pursue additional research activity in this patient population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-13